On Tuesday, Curis, Inc. announced that the FDA has allowed patient enrollment to resume in the monotherapy phase of its TakeAim Leukemia Phase I/II trial studying emavusertib.
https://www.pharmalive.com/wp-content/uploads/2022/05/US-Bridging-Study-Not-Enough-as-FDA-Denies-Hutchmeds-Pancreatic-Cancer-Drug-BioSpace-5-2-22.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-30 09:30:252022-08-30 10:54:57FDA partially clears Curis leukemia trial in second August regulatory win
